We believe in the future of precision medicine

CytoDyn’s purpose is to help enhance the lives of patients with life-threatening diseases. Our mission is to alleviate human suffering and improve patients' quality of life through innovation and collaboration. We are committed to performing our duties with respect, integrity, and a unified vision of serving humanity. 

CytoDyn is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV. The CCR5 receptor is a protein located on the surface of various cells including white blood cells, stellate cells which produce scar tissue in the liver, cells that undergo malignant transformation, and is the predominant co-receptor needed for certain strains of HIV to infect healthy T-cells. The CCR5 receptor serves as a receptor for chemical attractants called chemokines. Chemokines are the key orchestrators of leukocyte trafficking by attracting immune cells to the sites of inflammation.

Leronlimab is a humanized monoclonal antibody that is a once-a-week subcutaneous injection that can also be administered intravenously. Leronlimab is a competitive rather than allosteric inhibitor of the CCR5 receptor. This mechanism of action of binding competitively to the CCR5 receptor differentiates leronlimab from all other CCR5 antagonists.

Leronlimab’s Mechanism of Action for Immuno-oncology

About Our Company

Arrow Down

Leronlimab for HIV

A Fully Humanized Monoclonal Antibody

Leronlimab (PRO 140) is a fully humanized monoclonal antibody directed against CCR5, a molecular portal used by HIV to enter T cells. Leronlimab (PRO 140) blocks the precise sites on CCR5 used by HIV to enter the cell thereby protecting healthy cells from viral entry.

Read More on Leronlimab

CCR5 for Cancer

Developing CCR5 Technology in Cancer Indications

Based on the work of leading oncologists and researchers who played an instrumental role in identifying the role of CCR5 in cancer indications, we continue to explore the role of leronlimab in oncology and have obtained promising results from various pre-clinical studies.

Read More on CCR5

The Science of Developing Monoclonal Antibodies

In the 1980s, a team of scientists developed a technique that fused a common type of tumor cell with a single mouse antibody-producing cell. The resulting hybrid cells all secreted the exact same antibody as the original mouse antibody-producing cell and thus came to be known as monoclonal antibodies. Since then, monoclonal antibodies have come to represent one of the fastest expanding opportunities in the biotechnology/pharma sector.

Learn About Our Science